Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors ; volume:41 ; number:6 ; day:23 ; month:4 ; year:2024 ; pages:2307-2323 ; date:6.2024
Advances in therapy ; 41, Heft 6 (23.4.2024), 2307-2323, 6.2024
- Creator
-
Pochopien, Michal
Tytuła, Anna
Toumi, Mondher
Falk, Aletta
Martone, Nicoletta
Hakimi, Zalmai
Eriksson, Daniel
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-02841-w
- URN
-
urn:nbn:de:101:1-2408060948269.688913961141
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pochopien, Michal
- Tytuła, Anna
- Toumi, Mondher
- Falk, Aletta
- Martone, Nicoletta
- Hakimi, Zalmai
- Eriksson, Daniel
- SpringerLink (Online service)
Other Objects (12)
Recombinant Factor VIII Concentrates
Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B
Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia
Electroimmunoassay of Factor IX in the Detection of Haemophilia B Carriers
Recombinant production of blood coagulation factor II, factor IX and innovative complement regulator MFHR1 in Physcomitrella patens
Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A
Expression and characterization of recombinant cobra venom factor
Modulation of Extravascular Binding of Recombinant Factor IX Impacts the Duration of Efficacy in Mouse Models
Recombinant factor VIIa, rFVIIa : update on clinical experiences
Recombinant factor VIIa rFVIIa : current and future indications
Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders
Recombinant Factor VIII Concentrates
Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B
Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia
Electroimmunoassay of Factor IX in the Detection of Haemophilia B Carriers
Recombinant production of blood coagulation factor II, factor IX and innovative complement regulator MFHR1 in Physcomitrella patens
Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A
Expression and characterization of recombinant cobra venom factor
Modulation of Extravascular Binding of Recombinant Factor IX Impacts the Duration of Efficacy in Mouse Models
Recombinant factor VIIa, rFVIIa : update on clinical experiences
Recombinant factor VIIa rFVIIa : current and future indications
Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders
Recombinant Factor VIII Concentrates
Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B
Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia
Electroimmunoassay of Factor IX in the Detection of Haemophilia B Carriers
Recombinant production of blood coagulation factor II, factor IX and innovative complement regulator MFHR1 in Physcomitrella patens
Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A
Expression and characterization of recombinant cobra venom factor
Modulation of Extravascular Binding of Recombinant Factor IX Impacts the Duration of Efficacy in Mouse Models
Recombinant factor VIIa, rFVIIa : update on clinical experiences
Recombinant factor VIIa rFVIIa : current and future indications